Streetbeat News

Analyst Ratings

AG

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on First Majestic Silver (NYSE:AG) but lowers the price target from $12.5 to $12.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:03 am

TIXT

BMO Capital analyst Keith Bachman has downgraded TELUS Intl (NYSE:TIXT) from Outperform to Market Perform and lowered the price target from $21 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:00 am

ACMR

Needham analyst Quinn Bolton has reiterated a 'Buy' rating on ACM Research (NASDAQ:ACMR) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:50 am

TNET

TD Cowen analyst Jared Levine has upgraded Trinet Group (NYSE:TNET) from Market Perform to Outperform and raised the price target from $95 to $125.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:49 am

TPH

Wolfe Research analyst Truman Patterson has upgraded Tri Pointe Homes (NYSE:TPH) from Peer Perform to Outperform and announced a $38 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:48 am

MFIC

Compass Point analyst Casey Alexander has upgraded MidCap Financial (NASDAQ:MFIC) from Neutral to Buy and set a price target of $14.75.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:47 am

SKT

Compass Point analyst Floris Van Dijkum has upgraded Tanger Factory Outlet (NYSE:SKT) from Neutral to Buy and set a price target of $26.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:46 am

MTSI

Needham analyst Quinn Bolton maintains a Buy rating on MACOM Technology Solutions (NASDAQ:MTSI) and raises the price target from $65 to $84.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:45 am

MCHP

Needham analyst Rajvindra Gill has reiterated a 'Buy' rating on Microchip Technology (NASDAQ:MCHP) and maintained a price target of $100.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:38 am

IMRX

Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Immuneering (NASDAQ:IMRX) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 9:37 am